Shane R Stecklein1, Anuja Jhingran1, Jennifer Burzawa2, Preetha Ramalingam3, Ann H Klopp1, Patricia J Eifel1, Michael Frumovitz4. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 4. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: mfrumovitz@mdanderson.org.
Abstract
OBJECTIVE: To analyze patterns of recurrence and survival and identify prognostic factors in women with neuroendocrine cervical cancer (NECC). METHODS: We reviewed patients with International Federation of Gynecology and Obstetrics stage I-IVA NECC who were enrolled in the Neuroendocrine Cervical Tumor Registry and treated with curative intent. Event-free survival (EFS) and overall survival (OS) according to disease and treatment characteristics were analyzed using the Kaplan-Meier method. RESULTS: Among 40 patients with NECC, 25 (62%) had small cell NECC, eight (20%) had large cell NECC, and seven (18%) had unspecified neuroendocrine histology. With a median follow-up of 21.5months, 32 patients (80%) experienced progression, and 28 (70%) died. For all patients, the 5-year EFS rate was 20%, and the 5-year OS rate was 27%. Patients with large cell NECC had significantly better median EFS (median not reached vs. 10.0months, p=0.02) and showed a trend toward better median OS (153months vs. 21months, p=0.08) than patients with other histologic types. In patients with early-stage clinically node-negative disease, chemoradiation was associated with significantly better median EFS than surgery (median not reached vs. 18.0months, p=0.04). CONCLUSIONS: Patients with large cell NECC have better outcomes than patients with other subtypes of NECC. In early-stage node-negative NECC, chemoradiation yields better EFS than surgery. Most patients with NECC, even those with no evidence of nodal disease at diagnosis, rapidly develop widespread hematogenous metastases and die of their disease.
OBJECTIVE: To analyze patterns of recurrence and survival and identify prognostic factors in women with neuroendocrine cervical cancer (NECC). METHODS: We reviewed patients with International Federation of Gynecology and Obstetrics stage I-IVA NECC who were enrolled in the Neuroendocrine Cervical Tumor Registry and treated with curative intent. Event-free survival (EFS) and overall survival (OS) according to disease and treatment characteristics were analyzed using the Kaplan-Meier method. RESULTS: Among 40 patients with NECC, 25 (62%) had small cell NECC, eight (20%) had large cell NECC, and seven (18%) had unspecified neuroendocrine histology. With a median follow-up of 21.5months, 32 patients (80%) experienced progression, and 28 (70%) died. For all patients, the 5-year EFS rate was 20%, and the 5-year OS rate was 27%. Patients with large cell NECC had significantly better median EFS (median not reached vs. 10.0months, p=0.02) and showed a trend toward better median OS (153months vs. 21months, p=0.08) than patients with other histologic types. In patients with early-stage clinically node-negative disease, chemoradiation was associated with significantly better median EFS than surgery (median not reached vs. 18.0months, p=0.04). CONCLUSIONS:Patients with large cell NECC have better outcomes than patients with other subtypes of NECC. In early-stage node-negative NECC, chemoradiation yields better EFS than surgery. Most patients with NECC, even those with no evidence of nodal disease at diagnosis, rapidly develop widespread hematogenous metastases and die of their disease.
Authors: Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: Toyomi Satoh; Yuji Takei; Isabelle Treilleux; Mojgan Devouassoux-Shisheboran; Jonathan Ledermann; Akila N Viswanathan; Sven Mahner; Diane M Provencher; Linda Mileshkin; Elizabeth Åvall-Lundqvist; Patricia Pautier; Nicholas Simon Reed; Keiichi Fujiwara Journal: Int J Gynecol Cancer Date: 2014-11 Impact factor: 3.437
Authors: Stephen G Spiro; Lindsay E James; Robin M Rudd; Colin W Trask; Jeffrey S Tobias; Michael Snee; David Gilligan; Philip A Murray; Mary Carmen Ruiz de Elvira; Katy M O'Donnell; Nicole H Gower; Peter G Harper; Allan K Hackshaw Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Akila N Viswanathan; Michael T Deavers; Anuja Jhingran; Pedro T Ramirez; Charles Levenback; Patricia J Eifel Journal: Gynecol Oncol Date: 2004-04 Impact factor: 5.482
Authors: Sushmita Gordhandas; Brooke A Schlappe; Qin Zhou; Alexia Iasonos; Mario M Leitao; Kay J Park; Louise de Brot; Kaled M Alektiar; Paul J Sabbatini; Carol A Aghajanian; Claire Friedman; Oliver Zivanovic; Roisin E O'Cearbhaill Journal: Gynecol Oncol Rep Date: 2022-08-04
Authors: Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek Journal: BMC Cancer Date: 2018-05-04 Impact factor: 4.430